Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Obesity: early-phase trial registry
306 of 1,057 indexed Obesity trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3 of 28,707 conditions by registered trial count.
1,057 US clinical trials · 306 currently recruiting · #3 of 28,707 conditions by registered trial count
Obesity: 1,057 US clinical trials tracked, 306 recruiting.
Obesity is the subject of 1,057 registered US clinical trials on ClinicalTrials.gov, 306 of them currently open to new participants. 107 are in Phase 3-4 (later-stage) and 196 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 48 of these trials.
Enrollment posture brief
Registry condition obesity
OPEN 306 | RECR 29% | LATE 107 | EARLY 196 | RANK #3 | SPON 48
Volume-matched condition peers
Nearest open-share peer: Metastatic Pancreatic Adenocarcinoma (29% recruiting · 38 trials)
Obesity lists 306 open slots (29% of 1,057 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Obesity on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Obesity is recruiting below its size-band peers.
306 of 1,057 indexed trials (28.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Obesity trials is spread across many organizations.
Eli Lilly and Company accounts for 48 of 1,057 trials (4.5%). 314 distinct sponsors appear on at least one study for this condition label.
-
Typical Obesity enrolment sits around 90 participants.
Median target enrolment is 90 among the 1,054 trials that report a genuine target (sentinel values excluded). 555 of those (52.7%) plan for fewer than 100 participants.
-
Obesity research is mostly interventional.
894 interventional and 163 observational studies make up this index (84.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
1,057 total, page 1 of 22
Personalized Responses to Dietary Composition Trial 3
Zoe Global Limited
NCT04735835
Research Framework Exploring Sleep Health
Scripps Translational Science Institute
NCT05197738
International Weight Control Registry
Tufts University
NCT04907396
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Amgen
NCT07037433
Triage Survey for Cardiovascular, Obesity, and Related Endocrine Trial Eligibility
Brooklyn Clinical Research
NCT06412536
Endoscopic Bariatric Therapies (EBTs): A Retrospective and Prospective Multicenter Registry
Weill Medical College of Cornell University
NCT04494048
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
Currax Pharmaceuticals
NCT06098079
Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.
Clindove Research
NCT07106879
Motivational Wellness Coaching to Reduce Childhood Obesity in Families and Kids
Kaiser Permanente
NCT05143697
Advancing Biopsychosocial Care Training Initiative
Washington University School of Medicine
NCT07049861
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Amgen
NCT07037459
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
National Heart, Lung, and Blood Institute (NHLBI)
NCT01143454
Optimizing a Mobile Health Platform for Sleep Promotion and Obesity Prevention in Children
Children's Hospital of Philadelphia
NCT05703347
Community Park-Based Programs for Health Promotion: Fit2Play Prospective Cohort Study
Duke University
NCT06595251
New Heart Imaging Techniques to Evaluate Possible Heart Disease
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT01399385
Building Connections
Massachusetts General Hospital
NCT07091032
Identification of Phenotypic Factors That Predict Success for Weight Loss and Long-term Weight Maintenance
University of Michigan
NCT02043457
Healthy Start: Exploring the Fuel-mediated Programming of Neonatal Growth
University of Colorado, Denver
NCT02273297
Physical and Behavioral Traits of Overweight and Obese Adults
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00428987
Diabetes and Heart Disease Risk in Blacks
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00001853
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Eli Lilly and Company
NCT07321886
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
Kailera
NCT07284875
Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)
Memorial Sloan Kettering Cancer Center
NCT05770570
Scalable TELeheaLth Cancer CARe: The STELLAR Program to Treat Cancer Risk Behaviors
Northwestern University
NCT05687604
Children s Growth and Behavior Study
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NCT02390765
Early Tracking of Childhood Health Determinants (ETCHED) Study
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT03481829
Facilitated Transitions From Postpartum to Primary Care Coordination for People With Chronic Conditions
Massachusetts General Hospital
NCT06557005
Family COMIDA (Consumo de Opciones Más Ideales De Alimentos) (Eating More Ideal Food Options)
Memorial Sloan Kettering Cancer Center
NCT07144800
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Eli Lilly and Company
NCT06143956
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
Kailera
NCT07284979
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
Eli Lilly and Company
NCT06993792
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
Novo Nordisk A/S
NCT07339423
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Eli Lilly and Company
NCT07282600
Community Park-Based Programs for Health Promotion: Active Older Adults Prospective Cohort Study
Duke University
NCT06604650
Youth-Onset Type 2 Diabetes and Heart Disease: The Young at Heart Prospective Cohort Study
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT06730113
Evaluation of Child Care Staff Weight Management Program
UNC Lineberger Comprehensive Cancer Center
NCT05656807
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Eli Lilly and Company
NCT07392190
Randomized Trial of Healthy Family Foundations
Penn State University
NCT05630482
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Eli Lilly and Company
NCT07369011
Efficacy Trial of Healthy Together ("Juntos")
University of Miami
NCT06489262
Strategies for Implementing a Postpartum Lifestyle Intervention in WIC Clinics
Tulane University
NCT06116149
Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health
University of California, Davis
NCT06230510
Pharmacogenetics of Response to GLP1R Agonists
University of Maryland, Baltimore
NCT05071898
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
Eli Lilly and Company
NCT06972459
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
Eli Lilly and Company
NCT06972472
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
Eli Lilly and Company
NCT07357415
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Eli Lilly and Company
NCT07035093
Collaborative Multi-level Obesity Intervention Engaging Underserved Communities Trial
Tulane University
NCT06835686
Avoid and Resist Strategies for Weight Management
Cedars-Sinai Medical Center
NCT05143931
Study to Investigate Genetic Causes of Severe Early Childhood Onset Obesity.
Columbia University
NCT01998750
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 95 |
| Phase 2 | 101 |
| Phase 3 | 69 |
| Phase 4 | 38 |
Top Sponsors
Named interventions
Most-linked intervention names on Obesity records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Obesity trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Obesity page
1,057 registered trials, 306 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 306 Obesity trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Obesity trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Obesity condition card totals 1,057 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.